Effectiveness of OZ439 as a Gametocytocidal and Transmission Blocking Agent (OZGAM)
A Proof-Of-Concept Study to Assess the Effectiveness of OZ439 as a Gametocytocidal and Transmission Blocking Agent in Experimental P. Falciparum Infection
Sponsor: Army Malaria Institute, Australia
This PHASE1/PHASE2 trial investigates Malaria and is currently completed. Army Malaria Institute, Australia leads this study, which shows 9 recorded versions since 2015 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Jan 2023 — Jul 2024 [monthly]
Completed PHASE1_PHASE2
-
Dec 2022 — Jan 2023 [monthly]
Completed PHASE1_PHASE2
-
Jan 2021 — Dec 2022 [monthly]
Completed PHASE1_PHASE2
▶ Show 4 earlier versions
-
Jun 2020 — Jan 2021 [monthly]
Completed PHASE1_PHASE2
-
Jun 2018 — Jun 2020 [monthly]
Completed PHASE1_PHASE2
-
Jul 2017 — Jun 2018 [monthly]
Completed PHASE1_PHASE2
Status: Active Not Recruiting → Completed
-
Jan 2017 — Jul 2017 [monthly]
Active Not Recruiting PHASE1_PHASE2
First recorded
Apr 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Army Malaria Institute, Australia
- Clinical Network Services (CNS) Pty Ltd
- Medicines for Malaria Venture
- Q-Pharm Pty Limited
- QIMR Berghofer Medical Research Institute
- Sullivan Nicolaides Pathology
For direct contact, visit the study record on ClinicalTrials.gov .